Boehringer signals intent in obesity

Hopes were raised around pivotal development earlier this month when Boehringer’s partner Zealand Pharma said phase 3 plans were being discussed. With mid-stage trials also completed in type 2 diabetes and Nash, this could mean a huge push for Boehringer – and a nice pay day for Zealand, which is eligible for up to €345m ($374m) in milestones and double digit royalties.